en
Scientific article
Open access
English

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

CollaboratorsMach, Nicolas
Published inBlood, vol. 134, no. 4, p. 353-362
Publication date2019-07-25
Abstract

The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m2 IV on day 1 of weeks 1-4 and repeated during weeks 12-15 in responding patients) or rituximab (same schedule) in combination with lenalidomide (15 mg orally daily for 18 weeks). Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 months. In total, 77 patients were allocated to rituximab monotherapy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score in each arm). A significantly higher CR/CRu rate at 6 months was documented in the combination arm by the investigators (36%; 95% confidence interval [CI], 26%-48% vs 25%; 95% CI, 16%-36%) and confirmed by an independent response review of computed tomography scans only (61%; 95% CI, 49%-72% vs 36%; 95% CI, 26%-48%). After a median follow-up of 4 years, significantly higher 30-month CR/CRu rates and longer progression-free survival (PFS) and time to next treatment (TTNT) were observed for the combination. Overall survival (OS) rates were similar in both arms (≥90%). Toxicity grade ≥3 was more common in the combination arm (56% vs 22% of patients), mainly represented by neutropenia (23% vs 7%). Addition of lenalidomide to rituximab significantly improved CR/CRu rates, PFS, and TTNT, with expected higher, but manageable toxicity. The excellent OS in both arms suggests that chemotherapy-free strategies should be further explored. This trial was registered at www.clinicaltrials.gov as #NCT01307605.

eng
Citation (ISO format)
ZUCCA, Emanuele et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. In: Blood, 2019, vol. 134, n° 4, p. 353–362. doi: 10.1182/blood-2018-10-879643
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0006-4971
19views
4downloads

Technical informations

Creation12/06/2023 3:38:48 PM
First validation03/20/2024 10:04:43 AM
Update time03/20/2024 10:04:43 AM
Status update03/20/2024 10:04:43 AM
Last indexation05/06/2024 6:13:24 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack